Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264471 | 0.95 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29372063 | 0.95 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL30107564 | 0.94 | CASP3 (0.54) | CASP3MDM4TP53MDM2BACE1 | |
| SCHEMBL29471034 | 0.93 | CASP3 (0.47) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL46349 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 | |
| SCHEMBL872021 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 | |
| SCHEMBL29362906 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 | |
| SCHEMBL3722284 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 | |
| SCHEMBL29357117 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 | |
| SCHEMBL30261869 | 0.91 | MDM4 (0.55) | CASP3MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324936-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-10-13 | — | — | US | claimed |
| EP-3986919-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-27 | — | — | EP | claimed |
| EP-4482857-A1 | MODIFIED IL-18 POLYPEPTIDES | Bright Peak Therapeutics AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| WO-2023161856-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-31 | — | — | WO | disclosed |
| EP-4200323-A2 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | Bright Peak Therapeutics AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022038417-A2 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | IL18, IL2, IL36G | CASP3 643/4885MDM4 821/4885TP53 181/4885 |
| US-20220324936-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | IAPP, GCG, GLP1R | CASP3 3574/4885MDM4 3308/4885TP53 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.